Evidence of Robust Memory T-cell Responses in Patients with Chronic Myeloproliferative Neoplasms Following Infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Overview

Journal Br J Haematol

Specialty Hematology

Date 2021 Mar 15

PMID 33719038

Citations 7

Authors

Patrick Harrington

Claire N Harrison

Richard Dillon

Deepti H Radia

Katayoun Rezvani

Kavita Raj

Claire Woodley

Natalia Curto-Garcia

Jennifer OSullivan

Jamie Saunders

Shahram Kordasti

Sahra Ali

Hugues de Lavallade

Donal P McLornan

Affiliations

Soon will be listed here.

Citing Articles

JAK inhibitors and COVID-19.

Levy G, Guglielmelli P, Langmuir P, Constantinescu S J Immunother Cancer. 2022; 10(4).

PMID: 35459733 PMC: 9035837. DOI: 10.1136/jitc-2021-002838.

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.

Buske C, Dreyling M, Alvarez-Larran A, Apperley J, Arcaini L, Besson C ESMO Open. 2022; 7(2):100403.

PMID: 35272130 PMC: 8795783. DOI: 10.1016/j.esmoop.2022.100403.

Chronic Myeloid Leukemia in Children: Immune Function and Vaccinations.

Suttorp M, Webster Carrion A, Hijiya N J Clin Med. 2021; 10(18).

PMID: 34575167 PMC: 8470625. DOI: 10.3390/jcm10184056.

Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021.

Saunders J, Curto-Garcia N, Sriskandarajah P, OSullivan J, Woodley C, Asirvatham S Hemasphere. 2021; 5(7):e609.

PMID: 34179698 PMC: 8225363. DOI: 10.1097/HS9.0000000000000609.

T cell-mediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19.

Fernandez-Ruiz M, Olea B, Almendro-Vazquez P, Gimenez E, Marcacuzco A, San Juan R Am J Transplant. 2021; 21(8):2785-2794.

PMID: 34092033 PMC: 8222887. DOI: 10.1111/ajt.16708.

References

Barbui T, Vannucchi A, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A . High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021; 35(2):485-493. PMC: 7789078. DOI: 10.1038/s41375-020-01107-y. View

McLornan D, Khan A, Harrison C . Immunological Consequences of JAK Inhibition: Friend or Foe?. Curr Hematol Malig Rep. 2015; 10(4):370-9. DOI: 10.1007/s11899-015-0284-z. View

Altmann D, Boyton R . SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Sci Immunol. 2020; 5(49). DOI: 10.1126/sciimmunol.abd6160. View

Grifoni A, Weiskopf D, Ramirez S, Mateus J, Dan J, Rydyznski Moderbacher C . Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020; 181(7):1489-1501.e15. PMC: 7237901. DOI: 10.1016/j.cell.2020.05.015. View

Vabret N, Britton G, Gruber C, Hegde S, Kim J, Kuksin M . Immunology of COVID-19: Current State of the Science. Immunity. 2020; 52(6):910-941. PMC: 7200337. DOI: 10.1016/j.immuni.2020.05.002. View

Heine A, Held S, Daecke S, Wallner S, Yajnanarayana S, Kurts C . The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013; 122(7):1192-202. DOI: 10.1182/blood-2013-03-484642. View

Channappanavar R, Fett C, Zhao J, Meyerholz D, Perlman S . Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol. 2014; 88(19):11034-44. PMC: 4178831. DOI: 10.1128/JVI.01505-14. View

Alimam S, Ann Timms J, Harrison C, Dillon R, Mare T, deLavallade H . Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms. Br J Haematol. 2020; 193(1):150-154. DOI: 10.1111/bjh.17096. View

de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A . Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013; 122(2):227-38. PMC: 5726329. DOI: 10.1182/blood-2012-11-465039. View

10.

de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K . Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica. 2010; 96(2):307-14. PMC: 3031700. DOI: 10.3324/haematol.2010.032664. View

11.

Peng Y, Mentzer A, Liu G, Yao X, Yin Z, Dong D . Broad and strong memory CD4 and CD8 T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol. 2020; 21(11):1336-1345. PMC: 7611020. DOI: 10.1038/s41590-020-0782-6. View

12.

Keohane C, Kordasti S, Seidl T, Perez Abellan P, Thomas N, Harrison C . JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. Br J Haematol. 2015; 171(1):60-73. DOI: 10.1111/bjh.13519. View